Posted by Michael Wonder on 21 Jun 2023
argenx announces US FDA approval of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalised myasthenia gravis
20 June 2023 - Efficacy of Vyvgart Hytrulo was established by demonstrating a comparable pharmacodynamic effect to Vyvgart in Phase 3 ADAPT-SC bridging study.
argenx today announced that the US FDA approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc). Vyvgart Hytrulo is an injection for subcutaneous use for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
